Is ARS Pharmaceuticals (SPRY) the Best Biotech Stock?

ARS Pharmaceuticals (SPRY) is a biotech stock that produces Neffy. Neffy is a nasal spray with epinephrine and is used to fight against allergic reactions. In my opinion, this is incredible because many people, including myself, are nervous about stabbing themselves in the leg and would much prefer a nose spray. Unlike an Epipen that will last for 12-18 months, Neffy lasts upwards of 30 months. Neffy is $200 for 2 nasal sprays which have 1 dose each, while and Epipen costs around $750 for 2 which also have 1 dose each. This means that Neffy is cheaper and lasts longer so over time you will save a lot of money.

Neffy was just recently released worldwide in August of 2024 and have lost money the last 3 years due to not having a product to sell. ARS Pharmaceuticals partnered with ALK-Abello in Q3 of 2024. ALK-Abello is a worldwide leader in the commercialization of allergy products. This will lead to more sales worldwide which will raise the stock price. The last 3 analyst to publicly review ARS Pharmaceuticals have on average, predicted that in the next 12 months the price of the stock will rise to $28.33. That prediction suggests that the stock will rise around 170% in 2025. Benzinga.com rates ARS Pharmaceuticals at a 4.7/5 which is considered as a strong buy by them.